stockportfolio.pro
Sunshine Biopharma, Inc. (SBFMW)
NasdaqCM
Sunshine Biopharma, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $21,121 | $71,410 | $228,426 | $4.35M | $24.09M | $34.87M | $36.31M |
| Gross profit | — | — | — | $10,071 | $45,563 | $110,596 | $1.70M | $8.34M | $10.67M | $12.26M |
| Net income | $-3.50M | $-1.04M | $-2.16M | $-1.66M | $-2.78M | $-12.44M | $-26.74M | $-4.51M | $-5.13M | $-5.98M |
| Net margin | — | — | — | -7860.9% | -3898.7% | -5444.4% | -615.4% | -18.7% | -14.7% | -16.5% |
Source: Sunshine Biopharma, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of Sunshine Biopharma, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SBFMW in your portfolio →
Sunshine Biopharma, Inc. financial history by metric
About Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Sunshine Biopharma, Inc. — frequently asked questions
What is Sunshine Biopharma, Inc.'s revenue?
Sunshine Biopharma, Inc. (SBFMW) reported revenue of $36.31M for fiscal year 2025, up 4.1% from the prior year, according to its SEC filings.
Is Sunshine Biopharma, Inc. profitable?
No — SBFMW reported a net loss of $-5.98M in fiscal 2025.
What is SBFMW's P/E ratio?
Sunshine Biopharma, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Sunshine Biopharma, Inc. growing?
SBFMW's revenue grew at roughly 247.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Sunshine Biopharma, Inc. have?
As of fiscal year 2025, SBFMW carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Sunshine Biopharma, Inc.'s gross margin?
SBFMW's gross margin was 33.8% in fiscal 2025 — gross profit of $12.26M on revenue of $36.31M.
What is Sunshine Biopharma, Inc.'s market cap?
Sunshine Biopharma, Inc. (SBFMW) has a market capitalization of about $0, based on the latest data in our nightly-refreshed cache.
When does Sunshine Biopharma, Inc.'s fiscal year end?
SBFMW's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Sunshine Biopharma, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.